chevron_leftBack
As of 15 June 2026, S.Biomedics Co., Ltd. has a market cap of $300.65M USD, ranking #18585 globally and #608 in South Korea.
It ranks #4297 in the Industrials sector, and #448 in the Specialty Business Services industry.
Key Stats
Market Cap
$300.65MUSD
456.39B KRW
Enterprise Value
$304.33MUSD
461.98B KRW
Revenue (TTM)
$10.9MUSD
16.55B KRW
EBITDA (TTM)
-$4.15MUSD
-6.3B KRW
Net Income (TTM)
-$5.35MUSD
-8.12B KRW
EBITDA Margin
-38%
Profit Margin
-49%
PS Ratio
27.6
PB Ratio
27.3
Company Profile
Country (HQ)
Sector
Industrials
Industry
Specialty Business Services
CEO
Dong-Wook Kim
open_in_new
Founded
2005
Website
sbiomedics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 6.5% | 5.6% | 3.1% | -0.6% | 44% | 54% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
304360
에스바이오메딕스는
ISIN: KR7304360001
Shares Out.:
Shares Outstanding:
12.385M1
Shares Float:
9.12M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
36,850 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About S.Biomedics Co., Ltd.
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration; CF-TED-N for the treatment of stroke; and CF-FECS-DF for the treatment of wound. The company provides testing services; and owns platform technologies for developing cell therapy products. The company has a strategic partnership with Catalent, Inc. for the development and manufacturing of TED-A9. S.Biomedics CO., LTD. was founded in 2005 and is headquartered in Seoul, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 352820
|
$7.15B
2K%
10.85T KRW
|
-
|
|
KRX: 377300
|
$5.04B
2K%
7.65T KRW
|
169.0
|
|
KRX: 0009K0
|
$2.08B
591%
3.15T KRW
|
627.7
|
|
KRX: 012750
|
$1.93B
542%
2.93T KRW
|
16.4
|
|
KRX: 131970
|
$1.67B
456%
2.54T KRW
|
69.0
|
|
KRX: 174900
|
$661.55M
120%
1.0T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: SHOP
|
$158.14B
52K%
|
129.8
|
|
STO: VSURE
|
$132.81B
44K%
114.8B EUR
|
-
|
|
NASDAQ: CTAS
|
$69.6B
23K%
|
36.8
|
|
LSE: REL
|
$63.62B
21K%
47.6B GBP
|
23.9
|
|
NASDAQ: PYPL
|
$45.83B
15K%
|
9.4
|
|
|
T
NEO: TRI
|
$41.8B
14K%
56.91B CAD
|
-
|
chevron_leftBack